Bird & Bird ATMD wins trade mark and passing off action for pharmaceutical giant, Allergan Inc.

Bird & Bird ATMD LLP's Intellectual Property team, including Alban Kang (Partner) and Oh Pin-Ping (Counsel), has secured a win for Allergan, Inc., the maker of well-known products such as BOTOX and LATISSE, in a trade mark infringement and passing off claim before the Singapore High Court.

In its Judgment in Allergan, Inc. and anor. v Ferlandz Nutra Pte Ltd, the court held that the defendant's promotion and sale of its cosmetic product "LASSEZ" touted to promote eyelash growth infringed Allergan's registered trade mark for "LATISSE" in Class 5 for "pharmaceutical product for the treatment of eyelashes", and also amounted to passing-off.

Allergan's trade mark infringement claim by reference to the defendant's use of the identical "LATISSE" mark in a comparative advertisement also succeeded. The court rejected the defendant's defence of "fair use" for comparative advertising under section 28(4) of the Trade Marks Act (Cap. 332) based on its finding that the advertisement was materially misleading.

The case is significant as it is the first local decision on the comparative advertising defence. It also marks the first time that the High Court considered the question of whether end-users should be included as part of the relevant public in the likelihood of confusion analysis for trade mark infringement where the subject mark is used in respect of a pharmaceutical product. The court held that the possibility of confusion amongst end-users should be taken into account in this case as the evidence showed that end-users were significantly involved in selecting the products.

News & Deals

More News & Deals

Deal

Bird & Bird advised 88 Energy on an oversubscribed placing to raise A$9.9m (£5.2m)

Apr 25 2024

Read More

Deal

Bird & Bird advises Ibaera Capital on the sale of its Rogozna gold development project to Strickland Metals

Apr 23 2024

Read More

News

Bird & Bird ATMD advised lead investor Hatch Blue in agritech startup Peptobiotics' US$6.2 million Series A funding

Apr 15 2024

Read More

Deal

Bird & Bird advises P2X Solutions on financing arrangement

Apr 15 2024

Read More

News

Bird & Bird advises EFESO on the acquisition of Aioneers GmbH

Apr 12 2024

Read More

News

Bird & Bird Dominates European Managing IP Awards with Nine Victories

Apr 11 2024

Read More